PD-1 blockade in early-stage lung cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

Early-stage non-small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.

Original languageEnglish (US)
Pages (from-to)425-435
Number of pages11
JournalAnnual review of medicine
Volume70
DOIs
StatePublished - Jan 27 2019

Keywords

  • NSCLC
  • PD-1 immunotherapy
  • early stage
  • neoadjuvant
  • nivolumab
  • non-small cell lung cancer
  • pembrolizumab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'PD-1 blockade in early-stage lung cancer'. Together they form a unique fingerprint.

Cite this